In recent trading session, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) saw 1,816,630 shares changing hands with its beta currently measuring 1.41. Company’s recent per share price level of $8.76 trading at -$0.66 or -7.01% at recent trade assigns it a market valuation of $1.4 Billion. That current trading price of IRWD’s stock is at a discount of -60.96% from its 52-week high price of $14.1 and is indicating a premium of 9.7% from its 52-week low price of $7.91. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.77 Million shares which gives us an average trading volume of 2.2 Million if we extend that period to 3-months.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) trade information
In the face of being in the red today for losing -7.01%, in the last five days IRWD remained trading in the green while hitting it’s week-highest on Tuesday, Jul 28 when the stock touched $9.89-1 price level, adding 11.53% to its value on the day. Ironwood Pharmaceuticals, Inc.’s shares saw a change of -34.26% in year-to-date performance and have moved -7.99% in past 5-day. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) showed a performance of -15.21% in past 30-days. Number of shares sold short was 24.84 Million shares which calculate 11.29 days to cover the short interests.
Ironwood Pharmaceuticals, Inc. (IRWD) estimates and forecasts
Statistics highlight that Ironwood Pharmaceuticals, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -22.6% of value to its shares in past 6 months, showing an annual growth rate of 5.26% while that of industry is 12.1. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -10% in the current quarter and calculating -67.5% decline in the next quarter. This year revenue growth is estimated to drop -15.4% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $86.24 Million for the same. And 5 analysts are in estimates of company making revenue of $94.43 Million in the next quarter that will end in September 01, 2020. Company posted $89.62 Million and $97.1 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -3.8% while estimating it to be -2.7% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 17.8% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 129.7% while estimates for its earnings growth in next 5 years are of 0%
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s Major holders
Insiders are in possession of 3.2% of company’s total shares while institution are holding 114.72% percent of that, with stock having share float percentage of 118.52%. Investors also watch the number of corporate investors in a company very closely, which is 276 institutions for Ironwood Pharmaceuticals, Inc. that are currently holding shares of the company. Wellington Management Company, LLP is the top institutional holder at IRWD for having 22.06 Million shares of worth $222.63 Million. And as of March 30, 2020, it was holding 13.84% of the company’s outstanding shares.
The second largest institutional holder is Brown Capital Management, Inc., which was holding about 17.96 Million shares on March 30, 2020. The number of shares represents firm’s hold over 11.27% of outstanding shares, having a total worth of $181.22 Million.
On the other hand, Vanguard Specialized-Health Care Fund and Brown Capital Management Small Company Fund are the top two Mutual Funds which own company’s shares. As of April 29, 2020, the former fund manager was holding 10902066 shares of worth $109.02 Million or 6.84% of the total outstanding shares. The later fund manager was in possession of 9.98 Million shares on March 30, 2020, making its stake of worth around $100.7 Million in the company or a holder of 6.26% of company’s stock.